The most surprising part of TrumpRx isn’t that drug prices dropped—it’s how quickly big pharma agreed to drop them when the deal bypassed the usual middlemen.
Story Snapshot
- Merck and Sanofi joined a new wave of drugmakers offering steep discounts through TrumpRx and Medicaid tied to “most favored nation” pricing.
- Headline cuts drew attention: Merck’s Januvia fell from about $330 to $100, and Sanofi listed insulin at $35 per month while also touting dramatic pricing for Plavix.
- The program’s structure matters as much as the numbers: voluntary agreements and a direct-to-consumer platform aim to pressure the supply chain, not just negotiate around it.
- Supporters see “America First” leverage over global pricing; skeptics point out some eye-popping discounts involve drugs with cheaper alternatives already available.
Merck and Sanofi joined a pricing push built on one simple message: stop overcharging Americans
In December, the Trump administration announced pricing agreements with nine pharmaceutical companies, putting Merck and Sanofi in the spotlight for consumer-facing cuts.
The promise wasn’t small savings from a pharmacy coupon rack; it was a bid to align certain U.S. prices with the lowest rates paid in other developed countries. The White House framed it as a direct strike on the long-running claim that Americans subsidize global drug discounts.
Merck, Sanofi are latest companies to add medications to TrumpRx https://t.co/zscR6X2RjQ
— FOX Business (@FoxBusiness) April 13, 2026
Merck’s poster child was Januvia, a diabetes medication with a reported drop from roughly $330 to $100, with Janumet also included in the broader push. Sanofi’s attention-grabbers included a $35-per-month insulin listing and a dramatic price for Plavix.
Those numbers travel fast because they hit kitchen-table anxiety: the chronic-condition prescriptions that don’t feel optional. The administration also bundled in non-price expectations—domestic investment pledges and even stockpile contributions—so the deal read like a hybrid of health and industrial policy.
How TrumpRx tries to change the game: direct-to-consumer pricing instead of PBM trench warfare
TrumpRx’s power play sits in its routing. Instead of forcing a traditional insurer-PBM-pharmacy loop to pass along savings, the platform pushes discounted pricing straight to patients and pairs it with Medicaid commitments.
That matters for cash-pay families, people between jobs, early retirees not yet on Medicare, and anyone staring down a deductible reset.
The administration’s “most favored nation” concept adds a blunt negotiating cudgel: if other wealthy countries can demand lower prices, the U.S. shouldn’t accept being the generous exception.
Trump tried a version of this idea in 2020 through an executive order focused on Medicare payment models, but courts and bureaucracy slowed it.
The post-2024 revival took a different route—voluntary manufacturer participation paired with public pressure—making it harder for opponents to claim that the government “seized” pricing, even as the political leverage remained unmistakable.
The discounts are real, but the details decide whether they change lives or just headlines
Axios and other coverage provided a needed reality check: some of the most jaw-dropping price drops involve drugs that already face generic competition or have expired patents, meaning patients can sometimes find low-cost alternatives outside any new platform.
That doesn’t make the announcement meaningless; it changes what success looks like. The real test is whether TrumpRx consistently lowers prices on high-spend, still-protected brand drugs where Americans feel trapped by monopoly pricing.
That tension showed up in the administration’s roster of examples beyond Merck and Sanofi—cancer, HIV, and specialty drugs, where list prices can resemble a mortgage payment.
If TrumpRx delivers large cuts there, it becomes more than a political trophy; it becomes a market signal that manufacturers will sacrifice margins to avoid regulation, public outrage, or to protect access.
If the biggest savings remain concentrated in categories with plenty of substitutes, the program risks becoming a well-marketed directory of discounts people could have found anyway.
Why pharma signed on: politics, market access, and a warning shot to global pricing strategies
Pharmaceutical companies rarely volunteer to compress U.S. pricing unless the alternative looks worse. This wave of agreements carried several pressures at once: the threat of future legislation, the reputational damage of defending high American prices, and the opportunity to present “patient access” wins while keeping tighter control over distribution.
Legal analysts also read the deals as “continued pressure,” not a one-and-done reform—an invitation to more companies to join, and a signal that holdouts could become targets of the next round of White House spotlighting.
What to watch next: the platform’s growth, Medicaid execution, and whether “MFN” survives contact with the market
TrumpRx’s early trajectory signaled speed: plans for a January debut, a platform live by February 2026 with more than 40 drugs, and expansion toward 61-plus drugs as additional companies joined.
Media reports highlighted newer additions like AbbVie and Genentech and teased more companies in the pipeline. That pace matters because it turns the program into a living catalog rather than a one-day announcement.
If seniors, caregivers, and cash-pay patients can reliably find meaningful savings, adoption becomes its own political firewall.
Execution will decide whether the program becomes a lasting consumer habit or a short-term victory lap. Three questions loom: Do the best discounts apply to the drugs that drive the worst household budgeting crises?
Can Medicaid implementations actually reflect the promised cuts without administrative backsliding? Do manufacturers continue to invest domestically and support stockpile commitments, or do those pledges fade once headlines move on? TrumpRx doesn’t need perfection to matter, but it does need repeatable savings people can verify at the counter.
Merck, Sanofi are latest companies to add medications to TrumpRx – Fox Business. Check GoodRX and others. https://t.co/8UNFNwvb6Q
— Ed Pageau (@1shaddowman) April 13, 2026
For readers tired of Washington food fights, TrumpRx offers a cleaner storyline than most: the president sets a blunt benchmark, companies accept it, and patients see posted prices without having to decode PBM fine print.
The skeptic’s takeaway also deserves airtime: some “savings” look bigger than they are when generics already exist, and voluntary pricing can evaporate.
The practical takeaway sits between them—use the discounts where they help, compare against existing options, and watch whether competition finally starts acting like competition.
Sources:
Nine more drugmakers meet Trump on pricing plans
Pharmaceutical Policy in Motion: Continued as Trump Inks Nine
TrumpRx signs agreement with nine new pharma manufacturers
TrumpRx: AbbVie, Genentech add prescription drugs
